Abstract
Abstract HIV-1 resistance testing has become an increasingly important feature in antiretroviral treatment and is commonly performed by genotyping. Currently, two different systems are being marketed, and despite being far from easy to use, they have achieved a high degree of quality. Modifications of the standard kit protocols may be advantageous in certain situations. Although resistance reports issued by these systems are based on decision rules, they nevertheless require considerable knowledge and skills by the user to draw useful clinical data out of detected resistance patterns. Both systems described here in detail have their advantages and disadvantages; a decision in favor of one or the other needs to be based on individual requirements. In the future, Microarray systems may achieve a leading position on the market.
Zusammenfassung
Zusammenfassung Die HIV-1-Resistenztestung wird ein immer bedeutenderer Bestandteil des Monitorings der antiretroviralen Therapie und erfolgt in der Regel mittels Genotypisierung. Zur Zeit sind zwei Systeme kommerziell erhältlich und obwohl diese technisch nicht zu den einfach durchführbaren Methoden gehören, haben sie doch einen hohen Grad an Qualität erreicht. Modifikationen der Standardprotokolle sind für bestimmte Fragestellungen durchaus von Vorteil. Obwohl beide Systeme auf Entscheidungsregeln basierende Resistenz-Reports beinhalten, braucht es das zusätzliche Wissen und die Erfahrung des Anwenders, um die detektierten Mutationsmuster in klinisch brauchbare Resultate überführen zu können. Beide der hier detailliert beschriebenen Systeme haben ihre Vor- und Nachteile. Die Entscheidung für das eine oder andere System muss aufgrund der individuellen Bedürfnisse getroffen werden. Microarray-Systemen könnte der Markt der Zukunft gehören.
References
1 Larder BA, Darby G, Richman DD. HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy. Science1989;243:1731–4.10.1126/science.2467383Search in Google Scholar PubMed
2 Larder BA, Kemp SD. Multiple mutations in HIV-1 reverse transcriptase confer high-level resistance to zidovudine (AZT). Science1989;246:1155–8.10.1126/science.2479983Search in Google Scholar PubMed
3 Gulick RM, Mellors JW, Havlir D, Eron JJ, Gonzalez C, McMahon D, et al. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med1997;337:734–9.10.1056/NEJM199709113371102Search in Google Scholar PubMed
4 Hammer SM, Squires KE, Hughes MD, Grimes JM, Demeter LM, Currier JS, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team. N Engl J Med1997;337:725–33.10.1056/NEJM199709113371101Search in Google Scholar PubMed
5 Staszewski S, Morales-Ramirez J, Tashima KT, Rachlis A, Skiest D, Stanford J, et al. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. Study 006 Team. N Engl J Med1999;341:1865–73.10.1056/NEJM199912163412501Search in Google Scholar PubMed
6 Gulick RM, Mellors JW, Havlir D, Eron JJ, Meibohm A, Condra JH, et al. 3-year suppression of HIV viremia with indinavir, zidovudine, and lamivudine. Ann Intern Med2000;133:35–9.10.7326/0003-4819-133-1-200007040-00007Search in Google Scholar PubMed
7 Preston BD, Poiesz BJ, Loeb LA. Fidelity of HIV-1 reverse transcriptase. Science1988;242:1168–71.10.1126/science.2460924Search in Google Scholar PubMed
8 Mansky LM, Temin HM. Lower in vivo mutation rate of human immunodeficiency virus type 1 than that predicted from the fidelity of purified reverse transcriptase. J Virol1995;69:5087–94.10.1128/jvi.69.8.5087-5094.1995Search in Google Scholar PubMed PubMed Central
9 Preston BD. Reverse transcriptase fidelity and HIV-1 variation. Science1997;275:228–9.10.1126/science.275.5297.228Search in Google Scholar PubMed
10 Ho DD, Neumann AU, Perelson AS, Chen W, Leonard JM, Markowitz M. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature1995;373:123–6.10.1038/373123a0Search in Google Scholar PubMed
11 Wei X, Ghosh SK, Taylor ME, Johnson VA, Emini EA, Deutsch P, et al. Viral dynamics in human immunodeficiency virus type 1 infection. Nature1995;373:117–22.10.1038/373117a0Search in Google Scholar
12 Egger M, Hirschel B, Francioli P, Sudre P, Wirz M, Flepp M, et al. Impact of new antiretroviral combination therapies in HIV infected patients in Switzerland: prospective multicentre study. Swiss HIV Cohort Study. BMJ1997;315:1194–9.10.1136/bmj.315.7117.1194Search in Google Scholar
13 Palella FJ, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med1998;338:853–60.10.1056/NEJM199803263381301Search in Google Scholar
14 Mocroft A, Ledergerber B, Katlama C, Kirk O, Reiss P, d'Arminio MA, et al. Decline in the AIDS and death rates in the EuroSIDA study: an observational study. Lancet2003;362:22–9.10.1016/S0140-6736(03)13802-0Search in Google Scholar
15 d'Arminio MA, Testa L, Adorni F, Chiesa E, Bini T, Moscatelli GC, et al. Clinical outcome and predictive factors of failure of highly active antiretroviral therapy in antiretroviral-experienced patients in advanced stages of HIV-1 infection. AIDS1998;12:1631–7.10.1097/00002030-199813000-00010Search in Google Scholar PubMed
16 van Roon EN, Verzijl JM, Juttmann JR, Lenderink AW, Blans MJ, Egberts AC. Incidence of discontinuation of highly active antiretroviral combination therapy (HAART) and its determinants. J Acquir Immune Defic Syndr Hum Retrovirol1999;20:290–4.10.1097/00042560-199903010-00012Search in Google Scholar PubMed
17 Wit FW, van Leeuwen R, Weverling GJ, Jurriaans S, Nauta K, Steingrover R, et al. Outcome and predictors of failure of highly active antiretroviral therapy: one-year follow-up of a cohort of human immunodeficiency virus type 1-infected persons. J Infect Dis1999;179:790–8.10.1086/314675Search in Google Scholar PubMed
18 Perrin L, Telenti A. HIV treatment failure: testing for HIV resistance in clinical practice. Science1998;280:1871–3.10.1126/science.280.5371.1871Search in Google Scholar PubMed
19 Gallego O, Ruiz L, Vallejo A, Clotet B, Leal M, Soriano V. Rate of Virological Treatment Failure and Frequencies of Drug Resistance Genotypes among Human Immunodeficiency Virus-Positive Subjects on Antiretroviral Therapy in Spain. J Clin Microbiol2002;40:3865–6.10.1128/JCM.40.10.3865-3866.2002Search in Google Scholar PubMed PubMed Central
20 Martinez-Picado J, DePasquale MP, Kartsonis N, Hanna GJ, Wong J, Finzi D, et al. Antiretroviral resistance during successful therapy of HIV type 1 infection. Proc Natl Acad Sci USA2000;97:10948–53.10.1073/pnas.97.20.10948Search in Google Scholar PubMed PubMed Central
21 Hermankova M, Ray SC, Ruff C, Powell-Davis M, Ingersoll R, D'Aquila RT, et al. HIV-1 drug resistance profiles in children and adults with viral load of <50 copies/ml receiving combination therapy. Am Med Assoc2001;286:196–207.10.1001/jama.286.2.196Search in Google Scholar
22 Rousseau MN, Vergne L, Montes B, Peeters M, Reynes J, Delaporte E, et al. Patterns of resistance mutations to antiretroviral drugs in extensively treated HIV-1-infected patients with failure of highly active antiretroviral therapy. J Acquir Immune Defic Syndr2001;26:36–43.10.1097/00042560-200101010-00005Search in Google Scholar
23 Aleman S, Soderbarg K, Visco-Comandini U, Sitbon G, Sonnerborg A. Drug resistance at low viraemia in HIV-1-infected patients with antiretroviral combination therapy. AIDS2002;16:1039–44.10.1097/00002030-200205030-00010Search in Google Scholar
24 Alexander CS, Dong W, Schechter MT, O'Shaughnessy MV, Strathdee SA, Mo T, et al. Prevalence of primary HIV drug resistance among seroconverters during an explosive outbreak of HIV infection among injecting drug users. AIDS1999;13:981–5.10.1097/00002030-199905280-00015Search in Google Scholar
25 Boden D, Hurley A, Zhang L, Cao Y, Guo Y, Jones E, et al. HIV-1 drug resistance in newly infected individuals. Ann Med Assoc1999;282:1135–41.10.1001/jama.282.12.1135Search in Google Scholar
26 Yerly S, Kaiser L, Race E, Bru JP, Clavel F, Perrin L. Transmission of antiretroviral-drug-resistant HIV-1 variants. Lancet1999;354:729–33.10.1016/S0140-6736(98)12262-6Search in Google Scholar
27 Duwe S, Brunn M, Altmann D, Hamouda O, Schmidt B, Walter H, et al. Frequency of genotypic and phenotypic drug-resistant HIV-1 among therapy-naive patients of the German Seroconverter Study. J Acquir Immune Defic Syndr2001;26:266–73.10.1097/00126334-200103010-00010Search in Google Scholar
28 Little SJ, Holte S, Routy JP, Daar ES, Markowitz M, Collier AC, et al. Antiretroviral-drug resistance among patients recently infected with HIV. N Engl J Med2002;347:385–94.10.1056/NEJMoa013552Search in Google Scholar
29 Wensing AM, Boucher CA. Worldwide transmission of drug-resistant HIV. AIDS Rev2003;5:140–55.Search in Google Scholar
30 D'Aquila RT, Schapiro JM, Brun-Vezinet F, Clotet B, Conway B, Demeter LM, et al. Drug resistance mutations in HIV-1. Top HIV Med2003;11:215–21.Search in Google Scholar
31 Hirsch MS, Brun-Vezinet F, Clotet B, Conway B, Kuritzkes DR, D'Aquila RT, et al. Antiretroviral drug resistance testing in adults infected with human immunodeficiency virus type 1: 2003 recommendations of an International AIDS Society-USA Panel. Clin Infect Dis2003;37:113–28.10.1086/375597Search in Google Scholar
32 Durant J, Clevenbergh P, Halfon P, Delgiudice P, Porsin S, Simonet P, et al. Drug-resistance genotyping in HIV-1 therapy: the VIRADAPT randomised controlled trial. Lancet1999;353:2195–9.10.1016/S0140-6736(98)12291-2Search in Google Scholar
33 Baxter JD, Mayers DL, Wentworth DN, Neaton JD, Hoover ML, Winters MA, et al. A randomized study of antiretroviral management based on plasma genotypic antiretroviral resistance testing in patients failing therapy. CPCRA 046 Study Team for the Terry Beirn Community Programs for Clinical Research on AIDS. AIDS2000;14:F83–F93.10.1097/00002030-200006160-00001Search in Google Scholar PubMed
34 Cingolani A, Antinori A, Rizzo MG, Murri R, Ammassari A, Baldini F, et al. Usefulness of monitoring HIV drug resistance and adherence in individuals failing highly active antiretroviral therapy: a randomized study (ARGENTA). AIDS2002;16:369–79.10.1097/00002030-200202150-00008Search in Google Scholar PubMed
35 Meynard JL, Vray M, Morand-Joubert L, Race E, Descamps D, Peytavin G, et al. Phenotypic or genotypic resistance testing for choosing antiretroviral therapy after treatment failure: a randomized trial. AIDS2002;16:727–36.10.1097/00002030-200203290-00008Search in Google Scholar PubMed
36 Tural C, Ruiz L, Holtzer C, Schapiro J, Viciana P, Gonzalez J, et al. Clinical utility of HIV-1 genotyping and expert advice: the Havana trial. AIDS2002;16:209–18.10.1097/00002030-200201250-00010Search in Google Scholar PubMed
37 Haupts S, Ledergerber B, Boni J, Schupbach J, Kronenberg A, Opravil M, et al. Impact of genotypic resistance testing on selection of salvage regimen in clinical practice. Antivir Ther2003;8:443–54.10.1177/135965350300800512Search in Google Scholar
38 Panel on Clinical Practices for Treatment of HIV. Guidelines for using antiretroviral agents among HIV-infected adults and adolescents. Recommendations of the Panel on Clinical Practices for Treatment of HIV. MMWR Morb Mortal Wkly Rep 2002;51:1–55.Search in Google Scholar
39 Deutsche AIDS Gesellschaft (DAIG), Österreichische AIDS Gesellschaft (ÖAG). [Antiretroviral therapy of HIV infection. German-Austrian guidelines]. Dtsch Med Wochenschr 2003;128 Suppl 1:S7–S18.10.1055/s-2003-39115Search in Google Scholar PubMed
40 Pozniak A, Gazzard B, Anderson J, Babiker A, Churchill D, Collins S, et al. British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy. HIV Med2003;4 Suppl 1:1–41.10.1046/j.1468-1293.4.s1.3.xSearch in Google Scholar
41 The EuroGuidelines Group for HIV resistance. European guidelines for the clinical management and treatment of HIV-infected adults in Europe. AIDS 2003;17 Suppl 2:S3–26.10.1097/00002030-200306002-00002Search in Google Scholar
42 Erali M, Page S, Reimer LG, Hillyard DR. Human immunodeficiency virus type 1 drug resistance testing: a comparison of three sequence-based methods. J Clin Microbiol2001;39:2157–65.10.1128/JCM.39.6.2157-2165.2001Search in Google Scholar PubMed PubMed Central
43 Kuritzkes DR, Grant RM, Feorino P, Griswold M, Hoover M, Young R, et al. Performance characteristics of the TRUGENE HIV-1 Genotyping Kit and the Opengene DNA Sequencing System. J Clin Microbiol2003;41:1594–9.10.1128/JCM.41.4.1594-1599.2003Search in Google Scholar PubMed PubMed Central
44 Cunningham S, Ank B, Lewis D, Lu W, Wantman M, Dileanis JA, et al. Performance of the applied biosystems ViroSeq human immunodeficiency virus type 1 (HIV-1) genotyping system for sequence-based analysis of HIV-1 in pediatric plasma samples. J Clin Microbiol2001;39:1254–7.10.1128/JCM.39.4.1254-1257.2001Search in Google Scholar PubMed PubMed Central
45 Sturmer M, Berger A, Doerr HW. Modifications and substitutions of the RNA extraction module in the ViroSeq HIV-1 genotyping system version 2: effects on sensitivity and complexity of the assay. J Med Virol2003;71:475–9.10.1002/jmv.10527Search in Google Scholar PubMed
46 Mackie N, Dustan S, McClure MO, Weber JN, Clarke JR. Detection of HIV-1 antiretroviral resistance from patients with persistently low but detectable viraemia. J Virol Methods2004;119:73–8.10.1016/j.jviromet.2004.02.015Search in Google Scholar PubMed
47 Elbeik T, Hoo BS, Campodonico ME, Dileanis J, Fay FF, Bortolozzi RL, et al. In vivo emergence of drug-resistant mutations at less than 50 HIV-1 RNA copies/mL that are maintained at viral rebound in longitudinal plasma samples from human immunodeficiency virus type-1-infected patients on highly active antiretroviral therapy. J Hum Virol2001;4:317–28.Search in Google Scholar
48 Sanger F, Nicklen S, Coulson AR. DNA sequencing with chain-terminating inhibitors. Proc Natl Acad Sci USA1977;74:5463–7.10.1073/pnas.74.12.5463Search in Google Scholar PubMed PubMed Central
49 Fontaine E, Riva C, Peeters M, Schmit JC, Delaporte E, Van Laethem K, et al. Evaluation of two commercial kits for the detection of genotypic drug resistance on a panel of HIV type 1 subtypes A through J. J Acquir Immune Defic Syndr2001;28:254–8.10.1097/00042560-200111010-00008Search in Google Scholar PubMed
50 Mracna M, Becker-Pergola G, Dileanis J, Guay LA, Cunningham S, Jackson JB, et al. Performance of AppliedBiosystems ViroSeq HIV-1 Genotyping System for sequence-based analysis of non-subtype B human immunodeficiency virus type 1 from Uganda. J Clin Microbiol2001;39:4323–7.10.1128/JCM.39.12.4323-4327.2001Search in Google Scholar PubMed PubMed Central
51 Jagodzinski LL, Cooley JD, Weber M, Michael NL. Performance characteristics of human immunodeficiency virus type 1 (HIV-1) genotyping systems in sequence-based analysis of subtypes other than HIV-1 subtype B. J Clin Microbiol2003;41:998–1003.10.1128/JCM.41.3.998-1003.2003Search in Google Scholar PubMed PubMed Central
52 Sturmer M, Doerr HW, Preiser W. Variety of interpretation systems for human immunodeficiency virus type 1 genotyping: confirmatory information or additional confusion? Curr Drug Targets Infect Disord2003;3:373–82.10.2174/1568005033481006Search in Google Scholar PubMed
53 Sturmer M, Doerr HW, Staszewski S, Preiser W. Comparison of nine resistance interpretation systems for HIV-1 genotyping. Antivir Ther2003;8:239–44.10.1177/135965350300800308Search in Google Scholar
54 Marlowe N, Shafer R, Leong H, Liu T, Shulse E, Zoccoli M. Comparative evaluation of the ViroSeq v2.6 interpretation algorithm for prediction of HIV-1 drug resistance from viral genotype. HIV Med2004;5:239–40.Search in Google Scholar
55 Shafer RW, Jung DR, Betts BJ, Xi Y, Gonzales MJ. Human immunodeficiency virus reverse transcriptase and protease sequence database. Nucleic Acids Res2000;28:346–8.10.1093/nar/28.1.346Search in Google Scholar PubMed PubMed Central
56 Shafer RW, Jung DR, Betts BJ. Human immunodeficiency virus type 1 reverse transcriptase and protease mutation search engine for queries. Nat Med2000;6:1290–2.10.1038/81407Search in Google Scholar
57 Rhee SY, Gonzales MJ, Kantor R, Betts BJ, Ravela J, Shafer RW. Human immunodeficiency virus reverse transcriptase and protease sequence database. Nucleic Acids Res2003;31:298–303.10.1093/nar/gkg100Search in Google Scholar
58 De Luca A, Cingolani A, Di Giambenedetto S, Trotta MP, Baldini F, Rizzo MG, et al. Variable prediction of antiretroviral treatment outcome by different systems for interpreting genotypic human immunodeficiency virus type 1 drug resistance. J Infect Dis2003;187:1934–43.10.1086/375355Search in Google Scholar
59 Kijak GH, Rubio AE, Pampuro SE, Zala C, Cahn P, Galli R, et al. Discrepant results in the interpretation of HIV-1 drug-resistance genotypic data among widely used algorithms. HIV Med2003;4:72–8.10.1046/j.1468-1293.2003.00131.xSearch in Google Scholar
60 Ravela J, Betts BJ, Brun-Vezinet F, Vandamme AM, Descamps D, Van Laethem K, et al. HIV-1 protease and reverse transcriptase mutation patterns responsible for discordances between genotypic drug resistance interpretation algorithms. J Acquir Immune Defic Syndr2003;33:8–14.10.1097/00126334-200305010-00002Search in Google Scholar
61 Torti C, Quiros-Roldan E, Keulen W, Scudeller L, Lo CS, Boucher C, et al. Comparison between Rules-Based Human Immunodeficiency Virus Type 1 Genotype Interpretations and Real or Virtual Phenotype: Concordance Analysis and Correlation with Clinical Outcome in Heavily Treated Patients. J Infect Dis2003;188:194–201.10.1086/376512Search in Google Scholar
62 Beddows S, Galpin S, Kazmi SH, Ashraf A, Johargy A, Frater AJ, et al. Performance of two commercially available sequence-based HIV-1 genotyping systems for the detection of drug resistance against HIV type 1 group M subtypes. J Med Virol2003;70:337–42.10.1002/jmv.10401Search in Google Scholar
63 Koch N, Tamalet C, Tivoli N, Fantini J, Yahi N. Comparison of two commercial assays for the detection of insertion mutations of HIV-1 reverse transcriptase. J Clin Virol2001;21:153–62.10.1016/S1386-6532(01)00153-6Search in Google Scholar
64 Sturmer M, Staszewski S, Doerr HW, Hertogs K. A 6-base pair insertion in the protease gene of HIV type 1 detected in a protease inhibitor-naive patient is not associated with indinavir treatment failure. AIDS Res Hum Retroviruses2003;19:967–8.10.1089/088922203322588314Search in Google Scholar PubMed
65 Grant RM, Kuritzkes DR, Johnson VA, Mellors JW, Sullivan JL, Swanstrom R, et al. Accuracy of the TRUGENE HIV-1 genotyping kit. J Clin Microbiol2003;41:1586–93.10.1128/JCM.41.4.1586-1593.2003Search in Google Scholar PubMed PubMed Central
66 Boni J, Pyra H, Gebhardt M, Perrin L, Burgisser P, Matter L, et al. High frequency of non-B subtypes in newly diagnosed HIV-1 infections in Switzerland. J Acquir Immune Defic Syndr1999;22:174–9.10.1097/00042560-199910010-00010Search in Google Scholar
67 Brodine SK, Starkey MJ, Shaffer RA, Ito SI, Tasker SA, Barile AJ, et al. Diverse HIV-1 subtypes and clinical, laboratory and behavioral factors in a recently infected US military cohort. AIDS2003;17:2521–7.10.1097/00002030-200311210-00016Search in Google Scholar
68 Chaix ML, Descamps D, Harzic M, Schneider V, Deveau C, Tamalet C, et al. Stable prevalence of genotypic drug resistance mutations but increase in non-B virus among patients with primary HIV-1 infection in France. AIDS2003;17:2635–43.10.1097/00002030-200312050-00011Search in Google Scholar
69 Hanna GJ, Balaguera HU, Freedberg KA, Werner BG, Steger Craven KA, Craven DE, et al. Drug-selected resistance mutations and non-B subtypes in antiretroviral-naive adults with established human immunodeficiency virus infection. J Infect Dis2003;188:986–91.10.1086/378280Search in Google Scholar
70 Jorgensen LB, Christensen MB, Gerstoft J, Mathiesen LR, Obel N, Pedersen C, et al. Prevalence of drug resistance mutations and non-B subtypes in newly diagnosed HIV-1 patients in Denmark. Scand J Infect Dis2003;35:800–7.10.1080/00365540310016916Search in Google Scholar
71 Perez-Alvarez L, Carmona R, Munoz M, Delgado E, Thomson MM, Contreras G, et al. High incidence of non-B and recombinant HIV-1 strains in newly diagnosed patients in Galicia, Spain: study of genotypic resistance. Antivir Ther2003;8:355–60.10.1177/135965350300800413Search in Google Scholar
72 Stuyver L, Wyseur A, Rombout A, Louwagie J, Scarcez T, Verhofstede C, et al. Line probe assay for rapid detection of drug-selected mutations in the human immunodeficiency virus type 1 reverse transcriptase gene. Antimicrob Agents Chemother1997;41:284–91.10.1128/AAC.41.2.284Search in Google Scholar
73 Sturmer M, Morgenstern B, Staszewski S, Doerr HW. Evaluation of the LiPA HIV-1 RT assay version 1: comparison of sequence and hybridization based genotyping systems. J Clin Virol2002;25 Suppl 3:S65–S72.10.1016/S1386-6532(02)00190-7Search in Google Scholar
74 Derdelinckx I, Van Laethem K, Maes B, Schrooten Y, De Schouwer K, De Wit S, et al. Performance of the VERSANT HIV-1 resistance assays (LiPA) for detecting drug resistance in therapy-naive patients infected with different HIV-1 subtypes. FEMS Immunol Med Microbiol2003;39:119–24.10.1016/S0928-8244(03)00240-2Search in Google Scholar
75 Kozal MJ, Shah N, Shen N, Yang R, Fucini R, Merigan TC, et al. Extensive polymorphisms observed in HIV-1 clade B protease gene using high-density oligonucleotide arrays. Nat Med1996;2:753–9.10.1038/nm0796-753Search in Google Scholar PubMed
76 Gunthard HF, Wong JK, Ignacio CC, Havlir DV, Richman DD. Comparative performance of high-density oligonucleotide sequencing and dideoxynucleotide sequencing of HIV type 1 pol from clinical samples. AIDS Res Hum Retroviruses1998;14:869–76.10.1089/aid.1998.14.869Search in Google Scholar PubMed
77 Hanna GJ, Johnson VA, Kuritzkes DR, Richman DD, Martinez-Picado J, Sutton L, et al. Comparison of sequencing by hybridization and cycle sequencing for genotyping of human immunodeficiency virus type 1 reverse transcriptase. J Clin Microbiol2000;38:2715–21.10.1128/JCM.38.7.2715-2721.2000Search in Google Scholar PubMed PubMed Central
78 Wilson JW, Bean P, Robins T, Graziano F, Persing DH. Comparative evaluation of three human immunodeficiency virus genotyping systems: the HIV-GenotypR method, the HIV PRT GeneChip assay, and the HIV-1 RT line probe assay. J Clin Microbiol2000;38:3022–8.10.1128/JCM.38.8.3022-3028.2000Search in Google Scholar PubMed PubMed Central
©2005 by Walter de Gruyter Berlin New York
This article is distributed under the terms of the Creative Commons Attribution Non-Commercial License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
